MASSACHUSETTS SCIENTISTS OVERVIEW

PharmaMar is is the only commercial company in the world dedicated entirely to the discovery of new pharmaceuticals from marine organisms. One of the company's drugs, with the trade name of Yondelis®, is rapidly nearing FDA and equivalent approvals in the U.S. and Europe. Yondelis is likely to become the first commercially available cancer treatment derived directly from a marine organism, and as such many in the marine biotechnology field and elsewhere are excitedly following its progress. Glynn Faircloth is the President and CEO of Pharmamar's U.S. subsidiary, Pharmamar USA. He is also the Vice-President of Preclinical Research and Development of the Pharmamar parent company.